Crinetics Pharmaceuticals (CRNX) Other Non-Current Liabilities (2024 - 2026)

Crinetics Pharmaceuticals' Other Non-Current Liabilities history runs 3 years deep, the most recent figure standing at $4.9 million for Q1 2026.

• In Q1 2026, Other Non-Current Liabilities rose 178.78% year-over-year to $4.9 million; the TTM figure through Mar 2026 stood at $4.9 million (up 178.78% YoY), while the FY2025 annual figure was $3.2 million, up 290.83% from the prior year.
• Other Non-Current Liabilities was $4.9 million for Q1 2026 at Crinetics Pharmaceuticals, up from $3.2 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $4.9 million in Q1 2026 to a low of $202000.0 in Q2 2024.
• Historically, Other Non-Current Liabilities has averaged $2.1 million across 3 years, with a median of $2.1 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Other Non-Current Liabilities soared 1055.45% in 2025, then surged 178.78% in 2026.
• A 3-year view of Other Non-Current Liabilities shows it stood at $829000.0 in 2024, then soared by 290.83% to $3.2 million in 2025, then surged by 52.04% to $4.9 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $4.9 million (Q1 2026), $3.2 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.